The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Soleno Therapeutics as the specialty pharmacy ...

The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.19 per share a year ago. These figures are ...

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago. These figures ...

Pennsylvania Attorney General Dave Sunday has called on consumers to verify their eligibility for refunds stemming from a $39 ...

Clene (CLNN) delivered earnings and revenue surprises of -38.02% and 59.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?